Although once considered unlikely, bioterrorism is now a reality in the United States since the anthrax cases began appearing in the fall of 2001. Intelligence sources indicate there are many countries and terrorist organizations that either possess biological weapons or are attempting to procure them. In the future it is likely that we will experience additional acts of bioterrorism. The CDC category A agents represent our greatest challenge because they have the potential to cause grave harm to the medical and public health systems of a given population. Thus, it is imperative that plans be developed now to deal with the consequences of an intentional release of any one or more of these pathogens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0733-8627(02)00005-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.
Microorganisms
December 2024
Targeted Therapy Team, Institute for Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
The COVID-19 and mpox crisis has reminded the world of the potentially catastrophic consequences of biological agents. Aside from the natural risk, biological agents can also be weaponized or used for bioterrorism. Dissemination in a population or among livestock could be used to destabilize a nation by creating a climate of terror, by negatively impacting the economy and undermining institutions.
View Article and Find Full Text PDFDevelopment of a novel sandwich immunoassay based on targeting recombinant Francisella outer membrane protein A for the diagnosis of tularemia.
Front Cell Infect Microbiol
September 2024
Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Article Synopsis
- * Researchers produced FopA antigen using a baculovirus system and generated specific antibodies by immunizing mice, then screened these using hybridoma and phage display technologies.
- * Two monoclonal antibodies (6B12 and 3C1) were successfully developed, leading to a sensitive sandwich ELISA for tularemia diagnosis with low detection limits, providing a more effective alternative to traditional tests.
A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model.
PLoS One
May 2024
CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
Tularemia is a zoonotic disease caused by the facultative intracellular gram-negative bacterium Francisella tularensis. F. tularensis has a very low infection dose by the aerosol route which can result in an acute, and potentially lethal, infection in humans.
View Article and Find Full Text PDFSystematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993-2023.
Clin Infect Dis
January 2024
Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
Article Synopsis
- Francisella tularensis is a highly infectious bacterium that causes tularemia and poses a potential bioterrorism risk, with just 10 organisms needed to cause disease.
- A systematic review of 8878 publications found 410 articles detailing 870 cases treated with various antibiotics, mostly from the U.S., Turkey, and Spain, primarily presenting as ulceroglandular and pneumonic forms.
- The study concluded that aminoglycosides, fluoroquinolones, and tetracyclines are generally effective, with ciprofloxacin showing particularly good outcomes for patients with pneumonic disease, resulting in no fatalities and fewer complications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!